大博医疗
(002901)
| 流通市值：105.48亿 | | | 总市值：151.37亿 |
| 流通股本：2.89亿 | | | 总股本：4.14亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 550,336,243.99 | 2,135,559,372.81 | 1,529,257,676.1 | 964,129,205.76 |
| 营业收入 | 550,336,243.99 | 2,135,559,372.81 | 1,529,257,676.1 | 964,129,205.76 |
| 二、营业总成本 | 421,393,517.53 | 1,759,930,445.84 | 1,262,754,773.03 | 815,182,154.53 |
| 营业成本 | 167,104,242.23 | 667,258,489.01 | 482,102,549.84 | 319,577,758.3 |
| 税金及附加 | 7,691,359.36 | 26,056,638.01 | 18,673,075.15 | 11,492,097.54 |
| 销售费用 | 152,207,552.48 | 629,643,104.44 | 467,317,956 | 301,914,331.11 |
| 管理费用 | 35,426,947.63 | 139,388,279.07 | 90,572,845.99 | 56,274,543.37 |
| 研发费用 | 76,398,441.76 | 306,869,754.43 | 214,640,411.75 | 135,797,967.17 |
| 财务费用 | -17,435,025.93 | -9,285,819.12 | -10,552,065.7 | -9,874,542.96 |
| 其中:利息费用 | 2,123,793.74 | 6,488,771.16 | 5,520,810.76 | 4,527,475.75 |
| 其中:利息收入 | 6,852,977.43 | 27,500,167.92 | 22,491,625.29 | 15,061,870.19 |
| 加:公允价值变动收益 | 2,299,539.21 | 3,109,446.61 | 1,040,853.13 | -5,039,907.91 |
| 加:投资收益 | 497,341.26 | 17,279,174.34 | 11,446,084.53 | 7,926,313.7 |
| 资产处置收益 | 479,491.48 | 271,978.74 | -278,340.85 | 89,550.57 |
| 资产减值损失(新) | -9,421,298.99 | -43,413,060.55 | -28,019,176.85 | -17,922,645.27 |
| 信用减值损失(新) | -451,739.89 | -5,793,529.74 | 4,237,821.73 | 3,264,356.95 |
| 其他收益 | 5,910,691.6 | 82,472,608.08 | 33,673,823.33 | 26,780,737.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 128,256,751.13 | 429,555,544.45 | 288,603,968.09 | 164,045,456.92 |
| 加:营业外收入 | 122,330.74 | 802,482.44 | 397,703.04 | 97,259.45 |
| 减:营业外支出 | 247,195.34 | 1,944,063.74 | 1,336,132.62 | 1,086,899.28 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 128,131,886.53 | 428,413,963.15 | 287,665,538.51 | 163,055,817.09 |
| 减:所得税费用 | 15,591,298.73 | 43,121,856.56 | 24,516,201.53 | 12,248,066.64 |
| 六、净利润 | 112,540,587.8 | 385,292,106.59 | 263,149,336.98 | 150,807,750.45 |
| 持续经营净利润 | 112,540,587.8 | 385,292,106.59 | 263,149,336.98 | 150,807,750.45 |
| 归属于母公司股东的净利润 | 103,101,566.47 | 356,803,430.03 | 239,875,968.2 | 138,243,990.01 |
| 少数股东损益 | 9,439,021.33 | 28,488,676.56 | 23,273,368.78 | 12,563,760.44 |
| (一)基本每股收益 | 0.25 | 0.86 | 0.58 | 0.33 |
| (二)稀释每股收益 | 0.25 | 0.86 | 0.58 | 0.33 |
| 八、其他综合收益 | 198,278.05 | -74,189.12 | -1,244,015.8 | -961,868.75 |
| 归属于母公司股东的其他综合收益 | 163,860.77 | -60,904.68 | -993,192.91 | -909,999.09 |
| 九、综合收益总额 | 112,738,865.85 | 385,217,917.47 | 261,905,321.18 | 149,845,881.7 |
| 归属于母公司股东的综合收益总额 | 103,265,427.24 | 356,742,525.35 | 238,882,775.29 | 137,333,990.92 |
| 归属于少数股东的综合收益总额 | 9,473,438.61 | 28,475,392.12 | 23,022,545.89 | 12,511,890.78 |
| 公告日期 | 2025-04-30 | 2025-04-24 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |